Encouraging progress, and so soon after the G0 achievement, which bodes well for the remaining work. Does anyone here have enough knowledge of the glyco-engineering benefits to be able to help us understand at what point it's a "game changer"? Mark has lauded the human glycan structure objectives as such in the past, but I'm not entirely clear if it is "binary" in terms of being beneficial beyond 98% for example, or if it's a sliding scale in terms of the benefits (potentially improved efficacy, reduced chance of AE's, etc.) and thus anything north of 75% is good and 100% is simply "as good as possible".
My understanding is rather than it's not binary.. and even 100% doesn't guarantee anything specific, but it does mean that in-vivo trials stand a better chance of success with 100% human glycan structures.
Is that incorrect or incomplete as a perspective? Could something more binary (scientifically, or commercially) be lurking should they hit a specific % in the glyco progress?
News 
Market Data 
Discover 
